Trial Profile
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Volasertib (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia
- Focus Adverse reactions
- Acronyms VIAC
- 03 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2016 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.
- 26 Oct 2016 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.